Publicaciones en las que colabora con María José Ríos Villegas (21)

2020

  1. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients

    AIDS (London, England), Vol. 34, Núm. 10, pp. 1497-1507

  2. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 11, pp. 2810-2817

2019

  1. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  2. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278

2018

  1. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients

    AIDS, Vol. 32, Núm. 11, pp. 1423-1430

  2. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2435-2443

2017

  1. Liver stiffness predicts variceal bleeding in HIV/HCVcoinfected patients with compensated cirrhosis

    AIDS, Vol. 31, Núm. 4, pp. 493-500

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255

  2. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

  3. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

    BMC Infectious Diseases, Vol. 15, Núm. 1

2013

  1. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

    Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653

  2. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain

    Clinical Infectious Diseases, Vol. 56, Núm. 1, pp. 143-150

2012

  1. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

    AIDS, Vol. 26, Núm. 13, pp. 1721-1724

  2. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

    Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726

2009

  1. Natural history of compensated hepatitis c virusrelated cirrhosis in HIV-infected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 8, pp. 1274-1282

2008

  1. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients

    AIDS, Vol. 22, Núm. 8, pp. 923-930

  2. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796

  3. Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932

2007

  1. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354